North America Glucagon-Like Peptide-1 (GLP-1) Agonist Market Insights Forecasts to 2032

• The North America Glucagon-Like Peptide-1 (GLP-1) Agonist Market Size was valued at USD multimillion in 2022.
• The market is growing at a CAGR of 4.7% from 2022 to 2032.

Market Overview

GLP-1 receptor agonists (GLP-1RAs) are a kind of pharmaceutical used to treat type 2 diabetes, and some are also authorized to treat obesity. This family of medicines has a reduced risk of producing hypoglycemia than sulfonylureas or meglitinides. GLP-1RAs have considerable anti-inflammatory and pulmonary protective effects, as well as a favorable influence on the makeup of gut bacteria. As a result, GLP-1RAs have been identified as promising candidates for treating COVID-19 infection in people with or without type 2 diabetes, as well as good antidiabetic (glucose-lowering) medications during the COVID-19 pandemic.

Report Coverage

This research report categorizes the market of North America glucagon-like peptide-1 (GLP-1) agonist market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the North America glucagon-like peptide-1 (GLP-1) agonist market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the North America glucagon-like peptide-1 (GLP-1) agonist market.

Driving Factors

Diabetes incidence has increased alarmingly in the North American area in recent years. Diabetes is at an all-time high in industrialized countries such as the United States and Canada, owing mostly to lifestyle changes. Diabetes is linked to a slew of health issues. Patients with diabetes must make several adjustments during the day to maintain normal blood glucose levels, including administering more insulin or consuming additional carbs while checking their blood glucose levels.

Market Segment

• In 2022, the liraglutide {victoza} segment is dominating the largest market share during the forecast period.

Based on the drugs, the North America glucagon-like peptide-1 (GLP-1) agonist market is segmented into dulaglutide {trulicity}, exenatide {byetta, and bydureon}, liraglutide {victoza}, lixisenatide {lyxumia}, and semaglutide {ozempic}. Among these segments, the liraglutide {victoza} segment dominates the largest market share during the forecast period. Liraglutide is often used alone or in conjunction with other drugs to manage high blood sugar levels. People with type 2 diabetes are given it. Liraglutide is also used to lower the risk of having a heart attack, stroke, or dying in persons who have type 2 diabetes and heart disease. It works by boosting insulin release in response to high blood sugar levels following a meal and lowering sugar production by the liver. When cerebrovascular illness other than heart failure or renal disease predominates, GLP1RAs are suggested over SLGT2 inhibitors.

• In 2022, the United States is leading the largest market share over the forecast period.

Based on the region, the North America glucagon-like peptide-1 (GLP-1) agonist market is classified into the United States, Canada, and the rest of North America. Among these segments, the United Kingdom dominates the largest market share during the forecast period. According to the Centers for Disease Control and Prevention National Diabetes Statistics Report 2022, more than 130 million individuals in the United States have diabetes or prediabetes. Diabetes is more frequent in people of color, those who reside in rural regions, and those with less education, poorer incomes, and worse health literacy.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the North America glucagon-like peptide-1 (GLP-1) agonist market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Astrazeneca
• Sanofi
• Eli Lilly and Company
• Pfizer Inc.
• Novo Nordisk A/S

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In January 2023, Semaglutide (Wegovy- Novo Nordisk) has been licensed by the US Food and Drug Administration for the treatment of obesity in pediatric patients aged 12 and above. The approval came as a consequence of the findings of phase 3a research published in the New England Journal of Medicine. For 68 weeks, participants in the experiment were given semaglutide or a placebo in addition to a lifestyle intervention. These two groups were compared in terms of safety, effectiveness, and tolerability.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2022 to 2032. Spherical Insights has segmented the North America Glucagon-Like Peptide-1 (GLP-1) Agonist Market based on the below-mentioned segments:

North America Glucagon-Like Peptide-1 (GLP-1) Agonist Market, By Drug

• Dulaglutide {Trulicity}
• Exenatide {Byetta and Bydureon}
• Liraglutide {Victoza}
• Lixisenatide {Lyxumia}
• Semaglutide {Ozempic}

North America Glucagon-Like Peptide-1 (GLP-1) Agonist Market, By Country

• United States
• Canada
• rest of North America